X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

Optimizing CDMO Competitiveness Through Pricing Innovation

Content Team by Content Team
18th August 2023
in Drug Development, News

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Contract Development and Manufacturing Organizations (CDMOs), which pharmaceutical companies increasingly delegate product development and manufacturing, operate in a fragmented market undergoing substantial consolidation. Yet, many CDMOs fail to fully capitalize on pricing projects, risking competitiveness. To thrive, they must rapidly overhaul commercial strategies, extracting deserved product and service value and integrating it into pricing for optimal profits.

Commonly, CDMOs adopt inconsistent, opaque, and short-term pricing strategies, focusing on costs and silos. This leads to intricate, location-dependent pricing structures. Instead, CDMOs should transition to unified cost-accounting methods and streamlined offer packages, reflecting value-added services.

Simplifying offers and harmonizing costs requires defining offerings and introducing standardization via standard hours, multiplied by applicable hourly rates. However, one-size-fits-all rates are insufficient; CDMOs must use differentiated cost rates by service line and department. Achieving this involves comparing artificial cost rates with actual rates, benchmarking, and then standardizing via markups or markdowns.

CDMOs often price based on work packages or milestones, which doesn’t account for varying activities’ complexities. Unlike straightforward costing in other industries, costing CDMO’s highly customized services proves intricate. Determining costs becomes subjective, and diverse hourly inputs and costing rates across sites exacerbate inconsistency.

To resolve these issues, a three-step approach is advised:

  • Break down services into specific work packages and define activities.
  • Allocate standard hours per activity across cost centers.
  • Define hourly rates per cost center, considering required activities.

Although seemingly straightforward, many CDMOs struggle with implementing this approach due to inertia and obscured consequences. Yet, its benefits are undeniable:

  • Efficient quoting process, saving time and enhancing client negotiations.
  • Improved internal performance by minimizing inter-departmental interactions.
  • Increased transparency through monitoring and benchmarking of standard hours.
  • Customized offers, utilizing tiered logic and value-adding services.

The global landscape features more than 400 CDMOs, each asserting their end-to-end service offerings. It’s widely understood that not all CDMOs are identical, as we each present our distinct value propositions. Innovators confront substantial pressures, including the rise of supply chain intricacies, shortages, and the need to evaluate an unprecedented number of CDMOs. An end-to-end integrated service provider collaborates closely with their clients, presenting a truly integrated solution that spans the entire spectrum, from initial drug discovery to eventual commercialization. This encompasses versatile fill-finish capabilities. A genuinely integrated, end-to-end partnership provides heightened flexibility, risk mitigation, enhanced timeline management, and overall cost reduction.

The diversity of biopharmaceutical pipelines is expanding, driven by novel modalities and delivery techniques, thereby amplifying the necessity for fill-finish capacity within the CDMO sector. Within the global expanse of more than 400 CDMOs, only a subset can boast fully incorporated, comprehensive drug product capabilities that align with the surging demand. A spectrum of products, spanning conventional monoclonal antibodies, fusion proteins, bispecifics, ADCs, enzymes, and next-generation antibody-based offerings like cell and gene therapies, all require the expertise of a CDMO proficient in fill-finish operations. The challenge doesn’t merely lie in meeting demand; it involves identifying a qualified, experienced fill-finish CDMO collaborator. An end-to-end integrated service provider’s extensive track record boasts over 500 commercial batches, seamlessly integrating drug substance and drug product capabilities to leverage their wealth of fill-finish experience.

Previous Post

Rising Analytics Use Shapes Pharmaceutical CDMO Industry

Next Post

Advancing Biopharmaceuticals With Novel Drug Modalities

Related Posts

Merck to Acquire Verona
Drug Development

Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

21st July 2025
ChiRhoClin LogiCare3PL Partners for Drug Distribution
News

ChiRhoClin, LogiCare3PL Partners for Drug Distribution

21st July 2025
Emerging Oral Small Molecule Drugs
Drug Development

Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

21st July 2025
Thermo Fisher and Sanofi Partners
Manufacturing

Thermo Fisher and Sanofi Partners for US Drug Manufacturing

21st July 2025
EMA Recommendations to Secure Anti D Immunoglobulins Supply
News

EMA Recommendations to Secure Anti-D Immunoglobulins Supply

15th July 2025
FDA Approves Oral Therapy for Treating Hereditary Angioedema
FDA Approvals

FDA Approves Oral Therapy for Treating Hereditary Angioedema

15th July 2025
Next Post

Advancing Biopharmaceuticals With Novel Drug Modalities

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In